REV Clinical
REV Clinical is a US-based clinical CRO providing end-to-end trial design, regulatory, biometrics, and rescue services for pharmaceutical, biotech, and medtech sponsors, with operational hubs in the US, India, and Australia via its Global Velocity Network™.
- Company typePrivate
- Founded2010
- HeadquartersBakersfield, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What REV Clinical does
REV Clinical is a US-headquartered contract research organization (CRO) founded in 2010 as CBCC Global Research and rebranded under its current name in January 2026. The company provides end-to-end clinical trial services for pharmaceutical, biotechnology, and medical-device sponsors, organized around six solution lines: Clinical Trial Design & Operations, Regulatory & Submission Expertise, Biometrics & Data Management, the proprietary Global Velocity Network™, Quality & Compliance, and Trial Rescue Services. Therapeutic specialization covers oncology, neurology, ophthalmology, and rare disease, with claimed depth in 17+ oncology indications and experience across first-in-human through pivotal and post-market studies.
The operational backbone is the Global Velocity Network™, a tri-country site and operational footprint concentrated in the United States (Bakersfield, CA headquarters), India (Ahmedabad subsidiary, acquired in 2012 from Vibgyor Scientific Research), and Australia (Melbourne office opened May 2026). The company reports partnerships with 500+ clinical sites, access to approximately 4,000 new oncology patients annually via the affiliated CBCC Oncology Center, 50+ regulatory inspections cleared since 2021 without material findings (FDA, EMA, ANVISA, ISO, CDSCO, MOH Kazakhstan), and a Track record of 15+ trial rescue engagements with >80% of rescued trials exceeding patient-recruitment targets.
REV Clinical generates revenue through fee-for-service, project-based clinical trial contracts priced by scope, phase, therapeutic area, and geographic reach, with multi-year contract cadences. Go-to-market is direct enterprise sales led by senior leadership engagement, supplemented by participation in industry conferences (ASRS, AAO, CPHI Milan, ASH, CNS Summit) and content marketing through its Knowledge Center. The company is privately held following a 2025 partnership with Edgewater Capital Partners, and employs 200+ professionals globally (with a separate firmographic count of 51-100 reported W-2 employees).
REV Clinical firmographics
Firmographics- Name
- REV Clinical
- Legal name
- REV Clinical
- Website
- https://revclinical.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- REV Clinical is a US-based clinical CRO providing end-to-end trial design, regulatory, biometrics, and rescue services for pharmaceutical, biotech, and medtech sponsors, with operational hubs in the US, India, and Australia via its Global Velocity Network™.
- Ownership category
- akta.pro rank
REV Clinical industry classification
Industry- Product category
- Contract Research Organization (CRO) / Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where REV Clinical is headquartered
LocationHeadquarters
- HQ city
- Bakersfield
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
REV Clinical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Services: REV Clinical operates as a Contract Research Organization (CRO) providing fee-for-service clinical trial services including trial design, regulatory submissions, biometrics, site management, and operational execution. Services are provided to pharmaceutical, biotech, and medtech sponsors on a project-by-project basis with pricing based on scope, phase, and geographic reach.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
REV Clinical product offering
Product offeringCore offering
REV Clinical is a US-based Contract Research Organization (CRO) that designs, manages, and executes clinical trials for pharmaceutical, biotech, and medtech sponsors. The company provides end-to-end services including clinical trial design and operations, regulatory submissions, biometrics and data management, quality compliance, and trial rescue services. It operates a proprietary Global Velocity Network™ of strategic sites across the United States, India, and Australia, with deep therapeutic expertise in oncology, neurology, ophthalmology, and rare disease.
Product overview
REV Clinical is a US-based clinical CRO providing a comprehensive suite of integrated clinical research services organized around six core offerings: Clinical Trial Design & Operations, Regulatory & Submission Expertise, Biometrics & Data Management, the Global Velocity Network™ (strategic site network across US, India, and Australia), Quality & Compliance, and Trial Rescue Services. The company specializes in four therapeutic areas: Oncology, Neurology, Ophthalmology, and Rare Disease. The Global Velocity Network™ serves as the operational backbone connecting site networks across strategic hub regions, while Quality & Compliance underpins all services through rigorous SOPs and regulatory compliance. The Trial Rescue Services offering extends the company's value proposition to troubled trials requiring rapid intervention.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Trial Design & Operations
Quantifiable outcome
- Exceeds patient recruitment targets for >80% of rescue trials
- +2 more outcomes
Companies that use REV Clinical
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
REV Clinical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
REV Clinical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CBCC Oncology CentercoreStrategic alliance with CBCC Oncology Center in Bakersfield, California provides access to world-class clinicians, facilities, and equipment, as well as approximately 4,000 new oncology patients annually. The center provides end-to-end care including screening, biospecimen collection/testing, imaging, infusions, injections, and surgeries within a 150,000-square-foot complex staffed by over 360 specialists. This partnership accelerates enrollment in REV's oncology trials conducted in the US.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
REV Clinical competitors and assessment
Company assessmentDirect peers
- Medpace Holdings: Mid-sized clinical CRO with concentrated therapeutic expertise (oncology, neurology, rare disease) and a reputation for operational rigor; competes head-to-head with REV for biotech and mid-cap pharma trials.
- Worldwide Clinical Trials: Mid-sized specialty CRO with strong neuroscience and oncology focus serving small to mid-sized biotech; closely comparable business model and target customer to REV Clinical.
- Premier Research: Specialty CRO with deep pediatric, oncology, and rare disease focus; competes directly with REV for niche clinical trial programs from emerging biotech sponsors.
- Clinipace Worldwide: Mid-sized full-service CRO emphasizing flexible, mid-tier biotech client engagement with therapeutic breadth including oncology; comparable customer profile and operational model to REV.
Emerging players
- Novotech: Asia-Pacific-headquartered CRO known for biotech-focused clinical trial services across the region; relevant as a regional capability comparator for REV's Global Velocity Network including its new Australia hub.
- Veristat: Smaller specialty CRO with biostatistics, regulatory, and clinical operations focus serving emerging oncology and rare disease sponsors; comparable business profile at a smaller scale than REV.
Broad incumbents
- IQVIA Holdings: Largest global CRO and clinical services provider; competes broadly with REV in oncology and other therapeutic areas but at vastly greater scale and technology depth.
- ICON plc: Top-tier global CRO with full-service clinical development capabilities; competing incumbent for the same pharma and biotech budgets as REV.
- Labcorp Drug Development (Fortrea): Large CRO spun out from Labcorp; competes in clinical trial services across all major therapeutic areas with central lab capabilities adjacent to REV's scope.
- Parexel International: Large full-service CRO with global trial operations and biopharmaceutical services; competes for biotech clinical trial engagements REV targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights6 records
Customer concentration
REV Clinical compliance and trust
Trust signalCompliance6 records
REV Clinical financial estimates
Financial estimateRevenue estimate
Valuation estimate
REV Clinical leadership team
Management profileNumber of profiles
Profiles14 records
REV Clinical subsidiaries and ownership
Company hierarchySubsidiaries1 record
REV Clinical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
REV Clinical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about REV Clinical
What does REV Clinical do?
REV Clinical is a US-based Contract Research Organization (CRO) that designs, manages, and executes clinical trials for pharmaceutical, biotech, and medtech sponsors. The company provides end-to-end services including clinical trial design and operations, regulatory submissions, biometrics and data management, quality compliance, and trial rescue services. It operates a proprietary Global Velocity Network™ of strategic sites across the United States, India, and Australia, with deep therapeutic expertise in oncology, neurology, ophthalmology, and rare disease.
Is REV Clinical a public or private company?
REV Clinical is a private company. It is classified as private equity controlled and is currently operating.
When was REV Clinical founded?
REV Clinical was founded in 2010. It employs 51 to 100 people.
Where is REV Clinical based?
REV Clinical is headquartered in Bakersfield, United States, in the North America region.
How does REV Clinical make money?
One revenue line is on record: clinical Trial Services.
Who are REV Clinical's main competitors?
Direct peers on record are Medpace Holdings, Worldwide Clinical Trials, Premier Research and Clinipace Worldwide. Emerging players are Novotech and Veristat. Broad incumbents are IQVIA Holdings, ICON plc, Labcorp Drug Development (Fortrea) and Parexel International.
Does REV Clinical have an API?
No public API is recorded for REV Clinical.
What industry is REV Clinical in?
REV Clinical's product category is Contract Research Organization (CRO) / Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.